Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 24, 2011

View Archived Issues

Clinical findings presented for sirukumab in lupus and rheumatoid arthritis

New mechanism explored for treating Alzheimer's disease

New LXR agonist displays promising antiatherosclerotic effects in vivo

Korean investigators discover new biomarker of disease activity in rheumatoid arthritis

Results reported from phase I trial of enavatuzumab in advanced solid tumors

Updated results presented from ongoing first-in-patient trial of PF-04691502

Amgen tests antibody-drug conjugate targeting EGFRvIII

New compounds for bone disorders prepared by Daiichi Sankyo

Astellas Pharma prepares novel NPT-IIb inhibitors

FDA approves Medtronic's iPro2 professional CGM system

Novel tyrosine-protein kinase SYK inhibitors designed by GSK

Transition Therapeutics set to close USD 5 million private placement

UCB decides on option agreement to license SYN-118

Japanese researchers synthesize new PDE4B inhibitors

Takeda Pharmaceuticals reports novel acetyl-CoA carboxylase inhibitors

Advaxis completes pre-IND meeting for ADXS-HER2

Neuralstem injects first patient with stem cells in cervical region of spine

Takeda files NDA for fixed-dose tablet of alogliptin/metformin

FDA approves Transcept's insomnia drug Intermezzo

Mesoblast and FDA agree on adult stem cell trial in type 2 diabetes

Summit's SMT-C1100 granted orphan drug status in Duchenne's muscular dystrophy

Phase II trial of RP-G28 in lactose intolerance completed

Aeterna Zentaris licenses anticancer agent to Hikma

Cipher submits amendment to NDA for novel acne treatment

NICE decides not to recommend Lucentis for treatment of macular edema

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...